SUSCA, SARA
 Distribuzione geografica
Continente #
NA - Nord America 226
EU - Europa 98
AS - Asia 93
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 420
Nazione #
US - Stati Uniti d'America 225
SG - Singapore 69
IT - Italia 50
IE - Irlanda 14
CN - Cina 12
GB - Regno Unito 8
SE - Svezia 8
FI - Finlandia 7
FR - Francia 4
ID - Indonesia 4
IN - India 4
VN - Vietnam 2
BR - Brasile 1
CA - Canada 1
CH - Svizzera 1
DE - Germania 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
MK - Macedonia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
TW - Taiwan 1
UA - Ucraina 1
Totale 420
Città #
Singapore 65
Chandler 34
Ann Arbor 16
Santa Clara 16
Columbus 14
Dublin 14
Ashburn 10
Lappeenranta 7
Turin 7
Catania 6
Medford 4
Milan 4
Naples 4
New York 4
Nyköping 4
Princeton 4
Washington 4
Guangzhou 3
Torino 3
Urbino 3
Bandung 2
Boston 2
Falls Church 2
Florence 2
Guiyang 2
Hebei 2
Jakarta 2
Modena 2
Nottingham 2
Rome 2
San Mauro Pascoli 2
Arcene 1
Auckland 1
Barcelona 1
Beijing 1
Bourne 1
Chengdu 1
Chioggia 1
Greenville 1
Grugliasco 1
Hangzhou 1
Hyderabad 1
Jacksonville 1
Kansas City 1
Katihar 1
Lausanne 1
London 1
Mountain View 1
Mumbai 1
Munich 1
Nijmegen 1
Norwalk 1
Philadelphia 1
Piraeus 1
Regina 1
Riverton 1
Sandston 1
Seattle 1
São Paulo 1
Wickford 1
Wilmington 1
Totale 278
Nome #
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease 68
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 57
Risankizumab shows high efficacy and maintenance in improvement of response until week 52 44
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 27
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 27
A new suture technique for flap closure in dermatologic surgery 27
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 26
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 25
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 25
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 23
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 21
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 17
Mask-related acne flares during the COVID era 17
Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience 12
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 11
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 9
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 6
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience 3
Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents 2
Totale 447
Categoria #
all - tutte 3.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.133


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 0 4
2020/202110 3 2 2 1 0 0 0 0 0 0 0 2
2021/202254 3 0 1 1 4 0 7 6 3 3 9 17
2022/2023110 6 9 3 3 9 20 6 21 13 0 12 8
2023/2024124 10 22 10 11 3 12 8 4 2 13 10 19
2024/2025145 3 46 13 35 48 0 0 0 0 0 0 0
Totale 447